Compare Amylx Pharmaceuticals Inc (AMLX) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Devon Energy Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.28 (market cap $1.98B), while Devon Energy Corp trades at $43.24 (market cap $48.71B). The key difference: Devon Energy Corp is far larger — about 24.6× Amylx Pharmaceuticals Inc's market cap, and Devon Energy Corp pays a 2.46% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DVN | |
|---|---|---|
Market Cap | $1.98B | $48.71B |
Sector | Health | Energy |
52-Week High | $18.70 | $52.07 |
52-Week Low | $7.64 | $31.74 |
Enterprise Value | $1.70B | $55.49B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Devon Energy (DVN) trades at $42.23, up 0.5% with neutral technical signals. The company shows strong fundamentals with a P/E of 11.76 and ROE of 15.13%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Positive sentiment includes 71% analyst buy ratings and a $60.55 consensus target, while activist investor TOMS Capital pushes for asset sales or company sale (Reuters, 2026-06-17).
DVN offers value with discounted valuation and $1B synergy potential from the Coterra merger, but faces oil price volatility and execution risks. The stock trades 30% below analyst targets, presenting upside if operational targets are met, though debt levels and margin compression require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
